Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
|Articles|September 1, 2010
Vision Expo West retooled for more benefit to optometrists
Vision Expo West in October in Vegas will offer some exciting new continuing education and technology.
Advertisement
Las Vegas-International Vision Expo West (VEW) 2010 will be held Oct. 7 to 9 at the Sands Expo and Convention Center here, with a variety of programs and continuing education sessions as well as some exciting new uses of technology.
Advertisement
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
The Independent Advantage S02 E07: Is your front desk missing opportunities?
5